Suppr超能文献

二磷酸腺苷四磷酸(血小板致密颗粒的组成部分)对血小板 P2Y1、P2Y12 和 P2X1 受体的激动剂和拮抗剂作用。

Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors.

机构信息

Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA.

出版信息

Thromb Res. 2010 Feb;125(2):159-65. doi: 10.1016/j.thromres.2009.11.006. Epub 2009 Nov 27.

Abstract

INTRODUCTION

Diadenosine 5',5'''-P(1),P(4)- tetraphosphate (Ap(4)A) is stored in platelet dense granules, but its effects on platelet function are not well understood.

METHODS AND RESULTS

We examined the effects of Ap(4)A on platelet purinergic receptors P2Y(1), P2Y(12) and P2X(1). Flow cytometry was used to measure the effects of Ap(4)A in the presence or absence of ADP on: a) P2Y(12)-mediated decrease in intraplatelet phosphorylated vasodilator stimulated phosphoprotein (VASP), b) P2Y(1)-mediated increase in platelet cytosolic Ca(2+), and c) P2X(1)-mediated intraplatelet entry of extracellular Ca(2+). ADP-stimulated platelet shape change (P2Y(1)-mediated) and aggregation (P2Y(1)- and P2Y(12)-mediated) were measured optically. Ap(4)A inhibited 3 microM ADP-induced: a) platelet aggregation (IC(50) 9.8+/-2.8 microM), b) P2Y(1)-mediated shape change, c) P2Y(1)-mediated increase in platelet cytosolic Ca(2+) (IC(50) 40.8+/-12.3 microM), and d) P2Y(12)-mediated decrease in VASP phosphorylation (IC(50)>250 microM). In the absence of added ADP, Ap(4)A had agonist effects on platelet P2X(1) and P2Y(12), but not P2Y(1), receptors.

CONCLUSION

Ap(4)A, a constituent of platelet dense granules, is a) an antagonist of platelet P2Y(1) and P2Y(12) receptors, where it inhibits the effects of ADP, and b) an agonist of platelet P2X(1) and P2Y(12) receptors.

摘要

简介

二腺苷 5',5'''-P(1),P(4)-四磷酸(Ap(4)A)储存在血小板致密颗粒中,但它对血小板功能的影响尚不清楚。

方法和结果

我们研究了 Ap(4)A 对血小板嘌呤能受体 P2Y(1)、P2Y(12)和 P2X(1)的影响。流式细胞术用于测量 Ap(4)A 在存在或不存在 ADP 的情况下对以下方面的影响:a)Ap(4)A 对 P2Y(12)介导的血小板内磷酸化血管扩张刺激磷蛋白(VASP)减少的影响,b)Ap(4)A 对 P2Y(1)介导的血小板胞质 Ca(2+)增加的影响,以及 c)Ap(4)A 对 P2X(1)介导的细胞外 Ca(2+)进入血小板的影响。ADP 刺激的血小板形态变化(P2Y(1)介导)和聚集(P2Y(1)和 P2Y(12)介导)通过光学方法进行测量。Ap(4)A 抑制 3μM ADP 诱导的:a)血小板聚集(IC(50)9.8+/-2.8μM),b)P2Y(1)介导的形态变化,c)P2Y(1)介导的血小板胞质 Ca(2+)增加(IC(50)40.8+/-12.3μM),以及 d)P2Y(12)介导的 VASP 磷酸化减少(IC(50)>250μM)。在没有添加 ADP 的情况下,Ap(4)A 对血小板 P2X(1)和 P2Y(12)受体具有激动剂作用,但对 P2Y(1)受体没有作用。

结论

Ap(4)A,血小板致密颗粒的组成部分,a)是血小板 P2Y(1)和 P2Y(12)受体的拮抗剂,在那里它抑制 ADP 的作用,以及 b)血小板 P2X(1)和 P2Y(12)受体的激动剂。

相似文献

3
Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets.
Platelets. 2003 Feb;14(1):15-20. doi: 10.1080/0953710021000062914.
6
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):501-9. doi: 10.1161/ATVBAHA.115.306885. Epub 2016 Jan 7.
7
Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells.
Eur J Pharmacol. 2001 Nov 2;430(2-3):203-10. doi: 10.1016/s0014-2999(01)01401-7.
8
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Eur J Med Chem. 2016 Jan 1;107:204-18. doi: 10.1016/j.ejmech.2015.10.055. Epub 2015 Nov 9.

引用本文的文献

1
Clopidogrel-Mediated P2Y Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.
JACC Basic Transl Sci. 2024 Mar 25;9(7):865-876. doi: 10.1016/j.jacbts.2024.03.003. eCollection 2024 Jul.
2
Effects of uridine and nucleotides on hemostasis parameters.
J Thromb Thrombolysis. 2023 May;55(4):626-633. doi: 10.1007/s11239-023-02793-y. Epub 2023 Mar 24.
3
Migraine signaling pathways: purine metabolites that regulate migraine and predispose migraineurs to headache.
Mol Cell Biochem. 2023 Dec;478(12):2813-2848. doi: 10.1007/s11010-023-04701-7. Epub 2023 Mar 22.
4
Synthesis and biological evaluation of derivatives of 8-azapurine as novel antiplatelet agents.
RSC Med Chem. 2021 Jul 13;12(8):1414-1427. doi: 10.1039/d1md00128k. eCollection 2021 Aug 18.
5
Immunothrombosis in Acute Respiratory Dysfunction of COVID-19.
Front Immunol. 2021 Jun 2;12:651545. doi: 10.3389/fimmu.2021.651545. eCollection 2021.
8
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):501-9. doi: 10.1161/ATVBAHA.115.306885. Epub 2016 Jan 7.
9
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Eur J Med Chem. 2016 Jan 1;107:204-18. doi: 10.1016/j.ejmech.2015.10.055. Epub 2015 Nov 9.
10
Blood cells: an historical account of the roles of purinergic signalling.
Purinergic Signal. 2015 Dec;11(4):411-34. doi: 10.1007/s11302-015-9462-7. Epub 2015 Aug 11.

本文引用的文献

1
Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists.
Drug Dev Res. 1998 Oct 1;45(2):52-66. doi: 10.1002/(SICI)1098-2299(199810)45:2<52::AID-DDR2>3.0.CO;2-V.
3
P2Y12 antagonism: promises and challenges.
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8. doi: 10.1161/ATVBAHA.107.160689. Epub 2008 Jan 3.
4
Nucleotide receptor signaling in platelets.
J Thromb Haemost. 2006 Nov;4(11):2317-26. doi: 10.1111/j.1538-7836.2006.02192.x.
7
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor.
Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002. doi: 10.1016/j.bcp.2004.06.026.
8
Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.
Br J Pharmacol. 2004 Aug;142(8):1325-31. doi: 10.1038/sj.bjp.0705885. Epub 2004 Jul 20.
9
Emerging roles for P2X1 receptors in platelet activation.
Platelets. 2004 May;15(3):131-44. doi: 10.1080/09537100410001682788.
10
Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.
Blood. 2004 Sep 15;104(6):1745-52. doi: 10.1182/blood-2004-02-0534. Epub 2004 Jun 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验